BioArctic – Statement regarding today’s trading halt
Stockholm, Sweden, March 21, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) comments on the decision today by Nasdaq Stockholm to halt trading in BioArctic due to large movements in the share price. The reaction followed Biogen’s and Eisai’s decision to discontinue the Phase 3 trials of their drug candidate aducanumab in Alzheimer’s disease, which is not the same as BioArctic’s drug candidate BAN2401. The two projects, aducanumab and BAN2401, are based on different antibodies. Eisai and BioArctic remain dedicated to the Alzheimer’s community and continue preparations for the